Follicular Lymphoma Flashcards

1
Q

What are the common symptoms at presentation for FL?

A

B Symptoms
Fatigue
Local mass effect of LN
Cytopenias

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Describe FL

A

Indolent Lymphoma
Follows a chronic, relapsing course
Median survival of 7-10 years

Minority little or no progressions
Spontaneous and prolonged remissions

20-30% transform to high grade

Incidence of 20-25% amongst B Cell lymphoma
Median age 60 yo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the main oncogenic events that occur in the development of FL?

A

Ectopic expression of B-cell lymphoma 2 (BCL2)
Changes in the epigenome

BCL2 - promotes an anti-apoptotic programme
- provides survival signals to the malignant cells

Changes in the epigenome due to:

  • Genetic inactivation of the histo economy methyltransferase MLL2
  • Genetic inactivation of the acetyltransferases CREB-binding protein (CREBBP)
  • Genetic inactivation of the E1A-binding protein p300 (EP300)
  • activation of his tone methyltransferase enhancer of zeste homologous (EZH2)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the immunophenotype of FL?

A

CD20+
CD10+
BCL2+
BCL6+

CD23+/-
CD5-
CD43-
CCND1+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Any characteristic chromosomal translocation of FL?

A

BCL2 t(14;18) in 90% of cases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the differential diagnosis for FL?

A

1) NLPHL
- small and scattered large cells
2) CLL
- CD5+, CD23+
- CD10-, BCL6-
3) MCL
- Cyclin D1 +, CD5+
4) MZL
- CD10-, BCL6-

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Anything in particular about FL with 1p36 deletions?

A
  • Predominant diffuse pattern in inguinal LN,
  • large localized mass
  • CD23+
  • Typically G1 or G2
  • good prognosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Anything about IRF4 translocations?

A

Usually DLBCL, but occasionally pure FL Grade 3B;
And often could be DLBCL + FL Grade 3B

Typically present with Waldeyer’s ring involvement
Often children/young adults

Locally aggressive, but responds well to chemo +/- RT

BCL2-
Should NOT be treated as low-grade FL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the Waldeyer’s ring?

A
Ring of lymphoid tissue in the pharynx.
Formed by:
- Palatine tonsils ('tonsils)
- pharyngeal tonsils
- tubal tonsils
- lingual tonsil 
- adenoids
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the suggestions that a histologically transformation has occurred?

A

LDH rising
Single site growing disproportionately
Extranodal disease develops
New B symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the indications for treatment in FL (Grades 1-2)?

A
Candidate for clinical trial
Symptoms
Threatened end-organ function
Cytopenia secondary to lymphoma
Bulky disease
Steady progression 

GELF Criteria:

1) LN
- 3 or more LN areas each 3 or more cm
- any nodal or Extranodal site 7cm or bigger
2) Blood
- Cytopenias (Plts, Leukocytes)
- Leukemia
3) Organ
- Splenomegaly
- Ascites/Pleural effusions
4) General
- B Symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the GELF criteria?

A

1) Blood
- Cytopenias (Plt 5x10^9 malignant cells)
2) Organ
- Splenomegaly
- pleural effusions/ascites
3) LN
- 3 or more LN regions, each 3cm or bigger
- any LN or Extranodal site 7cm or bigger
4) General
- B symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is FLIPI-2 ?

A
Age >60 yo
Long diameter of largest LN >6cm
BM involvement (stage)
Beta-2microglobulin increased (Serum marker)
Hb
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are first-line treatments for fit FL patients?

A
R-Bendamustine
RCHOP
RCVP
Rituximab (375mg/m2 weekly for 4 doses)
R-Lenalidomide 

Addition of R has shown to increase ORR, Response duration, PFS as well as possibly OS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are first-line therapies for FL who are elderly or infirm ?

A

1) Rituximab (375mg/m2 weekly for 4 doses) - preferred
2) Single-agent alkylators +/- Rituximab
- Chlorambucil
- Cyclophosphamide
3) Radioimmunotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are 2nd-line and subsequent therapies approved for FL?

A

1) Chemoimmunotherapy
2) Rituximab
3) Lenalidomide +/- R
4) Idelalisib
5) Fludarabine + Rituximab
6) RFND
- Rituximab, Fludarabine, Mitoxantrone, Dexamethasone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How do we give Idelalisib?

A

Small molecule inhibitors

Recommended dose is 150mg PO BD

Possible s/e:
- Fatal +/- serious hepatotoxicitis
>> stop if ALT/AST >5xULN
>> when transaminitis resolved, need to reduce dose to 100mg BD 
- severe diarrhea or colitis
>> severe diarrhea/colitis can be managed with systemic or nonabsorbable steroids 
- pneumonitis
- intestinal perforation 

When used for CLL, upon initiation of Idelalisib, transient increase in absolute lymphocyte count is expected in most patients

  • does not mean PD
  • may persist for several weeks on treatment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the grades of FL?

A

Grading is performed according to the number of blasts per hpf

Grade 1: 5 or less than 5 blasts/hpf
Grade 2: 6-15 blasts/hpf

Grade 3A: >15 blasts/hpf, centroblasts with intermingled centrocytes
Grade 3B: >15 blasts/hpf, pure sheets of blasts

19
Q

Tell me what you know about FL3B with cytogenetic abnormalities at BCL6 (3p27)

A

More similar to germinal center DLBCL than FL1-3A

A/w more aggressive clinical course

20
Q

What are the other variants of FL?

A

1) Pediatric-type FL:
- Rare variant of FL
- lack of BCL2 rearrangement and t(14;18)
- better prognosis than adult FL
- often cured with minimal therapy

2) Primary intestinal FL:
- common in small intestine, usually duodenum
- similar to those of nodal FL
- clinically indolent, localized disease
- survival appears excellent even w/o tx.

3) Other Extranodal FL
- usually localized disease
- systemic relapses rare

4) FL-in-situ
- Preservation of LN architecture
- incidental finding of focal strongly positive staining for BCL2 restricted to germinal centers
- also has strong staining for CD10 in involved follicles
- detection of t(14;18) by FISH
- has been reported in patients with prior FL or concurrent FL at other sites

21
Q

What is primary cutaneous follicle Centre lymphoma? (PC-FCL)

A

Defined as:

  • tumor of neoplastic follicle center cells,
  • includes centrocytes, variable number of centroblasts
  • with a follicular and diffuse or a diffuse growth pattern

Most common B-cell lymphoma of the skin

Indolent, rarely disseminates to extra cutaneous sites

BCL6+, CD10+ likely
BCL2 often negative

Excellent prognosis, 5y OS 95%

22
Q

What are the 3 trials that advocated for WW in advanced stage asymptomatic FL in the pre-Rituximab era?

A

1) Ardeshna 2003
- treatment arm: Chlorambucil
2) Brice 1997
- Arm 2: Prednimustine
- Arm 3: IFN
3) Young 1988
- ProMACE-MOPP + total nodal irradiation

23
Q

Which 2 criteria can we use to assess if a FL patient is suitable for WW approach?

A

1) BNLI

2) GELF Criteria

24
Q

What is the BNLI criteria?

A

Absence of any:

  • pruritus or B symptoms
  • rapid growth in 3 months
  • life threatening organ involvement
  • marrow infiltration causing Hb
25
Q

Describe the Ardeshna paper that compared Rituximab vs WW in asymptomatic FL. What is the result?

A

Ardeshna in ASH 2010

Inclusion criteria:

  • asymptomatic FL,
  • Stage II, III, IV
  • non-bulky
  • n=380

Primary endpoints:
- time to start of new treatment

3 arms:
A) Rituximab (375) weekly x4 –> Rituximab q2monthly
B) Rituximab (375) weekly x4 –> regular clinic visits
C) WW

Results:

  • 3y PFS: WW 30%, R–>O 60%, R–>MR 80%
  • TTNT: 46% (WW) vs 88% (MR) vs 78% (Rituximab induction)
  • improvements in mental adjustment to cancer scale score and illness coping style score
  • MR group did not show improvements in QoL cf WW group.
  • No difference in 5y OS, all ~60%

Conclusion: R mono therapy should be considered as a treatment option for patients with asymptomatic advanced stage low-tumor-burden FL.

26
Q

Examples of small cells Lymphoma

A
CLL/SLL
Mantle Cell Lymphoma
Splenic MZL
Hairy cell Leukemia
Lymphoplasmacytic lymphoma
Extranodal MZL (MALT) 
Nodal MZL
FL
27
Q

What is the usual immunophenotype of FL?

A
CD5-
CD10+
BCL6+
BCDL2+
T(14;18)+

85% of FL will be BCL2+ or t(14;18)+

27
Q

What is the median survival of FL

A

7-10years

28
Q

What is the rate of transformation to HG from FL?

A

20-30%

29
Q

What are the Germinal center neoplasm?

A

Burkitt’s Lymphoma
DLBCL - GC subtype
FL

30
Q

What are the post-Germinal Centre neoplasms?

A

Marginal Zone Lymphomas
DLBCL - ABC subtype
Multiple myeloma

31
Q

What are the pre-Germinal Center neoplasms?

A

CLL/SLL

Mantle Cell Lymphoma

32
Q

What is the FLIPI-I Criteria?

A

AAHLN

Age 60years and above
Ann Arbor Stage III/IV
Hb ULN
No. Of nodal sites 5 or more

33
Q

What is the risk group associated with FLIPI-I chart?

A

AAHLN
(Age, Ann Arbor Stage, Hb, LDH, No. Of nodal sites)

Low - 0-1 factor
Intermediate - 2 factors
High - 3 or more

34
Q

What is FLIPI-1 used for?

A

This is designed in pre-Rituximab era
Identifies patient with higher risk of transformation
Not validated prospectively to guide treatment
Used to guide prognosis and treatment in clinical trials.

35
Q

What is the evidence for R-chemotherapy ?

A

1) Hiddemann ASH 2005

N=400
Untreated, advanced stage FL

2 arms:

1) CHOP
2) CHOP

RESULTS:
RCHOP reduced the RR for treatment failure by 60%
TTTF: increased with R
ORR 96% vs 90%
Prolonged duration of remission increased as well
Superior OS with R chemo

========
2) Marcus JCO 2008
Prev untreated FL
Stage III/IV

2 arms:
RCVP vs CVP

RESULTS:
All outcome measures show improvement
OS 83% vs 77%

36
Q

What is the evidence for R-Benda?

A

Rummel ASH 2009

Advanced FL, MCL, Indolent NHL

2arms:
A) Bendamustine (90) D1, D2 + Rituximab D1 q28days
B) RCHOP

RESULTS:
CR 40% (R-Benda) vs 30%
PFS 50% vs 30%
PFS (FL) not reached vs 47
TTNT not reached vs 40m
R Benda with lesser risk of neutropenia/infections
37
Q

Any evidence for maintenance Rituximab in FL?

A

1) PRIMA study Salles Lancet 2011

Prev untreated G1-III FL. N=1200
3 different chemo regimens with R. RCHOP, RCVP, R-FCM
Those who achieved CR/PR then underwent a 2nd randomization n=1000:
A) Maintenance Rituximab (375) X 2 years
B) Observation

RESULTS:
3y PFS 75% (maintenance) vs 60%
2y CR+uCR 70% vs 50%
No difference in OS

38
Q

When to start maintenance Rituximab?

A

E4402 (RESORT) study

FL + Low tumor burden s/p frontline Rituximab (375) for 4 weeks
Those with CR/PR (n=300) randomized to:
A) Maintenance R every 3 months
B) Retreatment at Progression with R weekly for 4 months

RESULTS:

  • TTTF 4y (RR) 4y (MR)
  • 3y Freedom from cytotoxic: 80% (RR) vs 95% (MR)
39
Q

What are the consolidation therapy trials in FL?

A

1) FIT trial
- Morschhauser JCO 2008
2) SWOG 0016
- ASH 2011
3) SWOG 9911
- Fisher JCO 2005

40
Q

What do you know about radio-immunotherapy in FL?

A

1) FIT trial by Morschhauser. JCO 2008

CD20+Advanced FL with CR/CRu/PR to 1st one induction chemo
N=400

2 arms:

1) Rituximab (250) D0, 7 + Y-90-Ibritumomab 14.8MBq/kg D7
2) Observation

RESULTS:
8y PFS 40%(Y-90) vs 20%
Med PFS 4y vs 1 y 
TTT 8 y vs 3 y
Estimated 8y OS ~

============
2) SWOG 0016 trial by Press ASH 2011

Untreated advanced FL
N=550

2 arms:

1) RCHOP
2) CHOP–> Tositumomab 2 weeks later

RESULTS:
2y PFS 76% vs 80%(RIT)
2y OS 97% vs 93% (RIT)

Conclusion –> not significant

==========
3) Tositumomab alone. NEJM 2005 Kaminski et al
Stage 3/4 FL
S/p Tositumomab single dose–> I-labeled Tositumomab 1 week later

RESULTS:
75% with CR

5y PFS 60%
Med PFS 6years

41
Q

Under which conditions can Bendamustine not be used?

A

CrCl

42
Q

Tell me about Bortezomib in NHL

A

Proteasome inhibitor
Active as single agent in indolent NHL (FL, MZL)
Optimal dosing not established

Preclinical data suggest Bortezomib may enhance Rituximab efficacy